April 25, 2018 / 11:10 AM / in 6 months

BRIEF-U.S. FDA Clears Pluristem’S Phase III Study In Treatment Of Muscle Injury Following Hip Fracture Surgery

April 25 (Reuters) - Pluristem Therapeutics Inc:

* U.S. FDA CLEARS PLURISTEM’S PHASE III STUDY IN TREATMENT OF MUSCLE INJURY FOLLOWING HIP FRACTURE SURGERY

* PLURISTEM THERAPEUTICS INC - IN DISCUSSIONS WITH SEVERAL EU COUNTRIES TO APPROVE STUDY IN EUROPE

* PLURISTEM THERAPEUTICS INC - EXPECTS TO BEGIN PATIENT ENROLLMENT IN BOTH EUROPE AND U.S. DURING 2018 Source text for Eikon: Further company coverage: (Reuters.Briefs@thomsonreuters.com)

0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below